Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Oct;4(Suppl 1):S14.
doi: 10.21037/atm.2016.10.45.

ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics

Camillo Porta  1 , Silvia Chiellino  2
Affiliations
Editorial

ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics

Camillo Porta et al. Ann Transl Med. 2016 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

C Porta acted as a consultant and/or speaker for Pfizer, Novartis, Exelixis, Ipsen, BMS, Eisai, Peloton and Roche-Genentech; S Chiellino has no conflicts of interest to declare.

Comment on

References

    1. Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016;387:2008-16. 10.1016/S0140-6736(16)00559-6 - DOI - PMC - PubMed
    1. Massari F, Bria E, Maines F, et al. Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. Clin Genitourin Cancer 2013;11:471-6. 10.1016/j.clgc.2013.04.018 - DOI - PubMed
    1. Shen C, Kaelin WG, Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 2013;23:18-25. 10.1016/j.semcancer.2012.06.001 - DOI - PMC - PubMed
    1. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21. 10.1172/JCI24612 - DOI - PMC - PubMed
    1. Santoni M, Buti S, Conti A, et al. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol 2015;10:517-22. 10.1007/s11523-014-0356-3 - DOI - PubMed

LinkOut - more resources